Word: accessibly
(lookup in dictionary)
(lookup stats)
Dates: all
Sort By: most recent first
(reverse)
...speech delivered at Harvard Medical School, would limit prices in the 50 least developed countries and give back a portion of the profits gained in these countries toward programs to expand their health-care capacity. More surprisingly, GSK also announced that it would allow outside researchers access to some of its patented medical technologies in an effort to facilitate more research aimed at so-called “neglected diseases,” or diseases that currently suffer from a severe lack of research funding...
...profit corporation like GSK. The influence of pharmaceutical companies at universities is a controversial topic. We are often rightly cautioned that becoming too closely tied with industry may lead us to lose sight of our public interest mission. Yet when a major pharmaceutical company takes the lead in promoting access to medicines in developing countries, following Big Pharma would bring us more in line with our own core values as an educational nonprofit...
...spite of their important role in producing new drugs, universities have taken a back seat to pharmaceutical companies in determining the policy agenda for access to medicines. Patentable technologies created in universities are typically licensed to pharmaceutical companies to facilitate the development of useful, marketable end products. In addition to providing product development, these partnerships also frequently guarantee that the institution and the researcher will share in the profits through royalties. Yet, too often, the agreements used to create these partnerships contain no provisions preserving the rights of universities to grant access to the finished products. This means that...
...Squibb to jointly announce that they would permit the sale of low-priced generic drugs in South Africa, which led to a 96-percent reduction in the price of one first-line HIV treatment. More recently, the University of British Columbia has formalized a policy that will incorporate global access wherever possible into agreements with industry. These licensing policies for global access cost a negligible amount because markets in developing countries generate so little revenue. The benefits of these policies are significant: potentially life-saving interventions for millions of patients...
...Global access licensing is not a burden on industry relations, and it is appealing for donors seeking to fund university research. For example, in the year following UBC’s implementation of its global access policy in 2007, UBC increased the number of new technologies licensed, industry funding remained steady, and research funding from all sources, including government and non-profit, increased by over 15 percent...